Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
- AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
- Allegra, Allelock Face Stiff Competition from Generics in Anti-Allergic Drug Market
February 14, 2013
- Otsuka Holdings Pharmaceutical Sales Up 3.4% in April-December Thanks to Abilify Sales Hike
February 14, 2013
- Samsca 7.5 mg Tablets Approved: Otsuka
February 14, 2013
- Novartis Will Explain to Doctors that 2009 Article on Diovan Is Invalid: President Mitani
February 13, 2013
- Bristol-Myers, Pfizer Underline Eliquis’s Superiority vs. Warfarin
February 13, 2013
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
- Sales of 10 Top European, US Drug Makers See Sharp Declines in 2012 Due to Patent Cliff
February 13, 2013
- Naglazyme Sales and Development Funds Grow for AnGes MG in April-December
February 12, 2013
- Eli Lilly to Discontinue Development of Tabalumab for RA
February 12, 2013
- Will Lotriga Create a New Market or Battle Head to Head with Epadel?
February 12, 2013
- Ethical Drug Sales Down 2.5% in December: Crecon Report
February 8, 2013
- Seikagaku to Initiate PII Trial in Japan of Knee Osteoarthritis Treatment
February 8, 2013
- Chugai Applies for Once-Weekly Herceptin for Postoperative Adjuvant Chemotherapy in Breast Cancer Based on Data from Public Domain
February 8, 2013
- Asahi Kasei Pharma Reports Strong Growth for April-December 2012; Sales of Teribone Break 12 Billion Yen Mark
February 8, 2013
- Pfizer Confident about Joining Top 3 in Japan Generic Sales by around 2015: Unit Chief Matsumori
February 7, 2013
- DSP President Expects Launch of PMDA-WEST, Says Kansai Firms Are at Disadvantage
February 7, 2013
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…